CLDI vs. IMMP, PYXS, TRVI, PROC, SCLX, MGNX, PRLD, ATAI, CMPX, and GNFT
Should you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Immutep (IMMP), Pyxis Oncology (PYXS), Trevi Therapeutics (TRVI), Procaps Group (PROC), Scilex (SCLX), MacroGenics (MGNX), Prelude Therapeutics (PRLD), Atai Life Sciences (ATAI), Compass Therapeutics (CMPX), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.
Calidi Biotherapeutics (NYSE:CLDI) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 34.5% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Immutep had 8 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 8 mentions for Immutep and 0 mentions for Calidi Biotherapeutics. Immutep's average media sentiment score of 0.91 beat Calidi Biotherapeutics' score of 0.00 indicating that Immutep is being referred to more favorably in the news media.
Calidi Biotherapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500.
Calidi Biotherapeutics presently has a consensus target price of $16.67, indicating a potential upside of 1,343.00%. Immutep has a consensus target price of $8.00, indicating a potential upside of 214.96%. Given Calidi Biotherapeutics' higher possible upside, equities analysts clearly believe Calidi Biotherapeutics is more favorable than Immutep.
Immutep received 311 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users.
Immutep has higher revenue and earnings than Calidi Biotherapeutics.
Summary
Immutep beats Calidi Biotherapeutics on 7 of the 12 factors compared between the two stocks.
Get Calidi Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calidi Biotherapeutics Competitors List
Related Companies and Tools
